Sana Biotechnology
Yahoo Finance • last month
Sana Biotechnology, Inc. (SANA): Jeff Bezos Is Buying This Stock Now
We recently compiled a list of the 8 Stocks Jeff Bezos is Buying.In this article, we are going to take a look at where Sana Biotechnology, Inc. (NASDAQ:SANA) stands against the other stocks Jeff Bezos is buying. 'We are Famously Unprofita... Full story
Yahoo Finance • 3 months ago
Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer
Sana Biotechnology, Inc SEATTLE, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of Dhaval Patel,... Full story
Yahoo Finance • 12 months ago
Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System
Sana Biotechnology, Inc SEATTLE, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the publication in Blood of an a... Full story
Yahoo Finance • last year
Sana Biotechnology to Present at November and December 2023 Investor Conferences
SEATTLE, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor... Full story
Yahoo Finance • last year
Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes
Goal is to report UP421 proof of concept data in 2023 and 2024 Potential to remove immunosuppression from islet cell transplantation SEATTLE, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused... Full story
Yahoo Finance • last year
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis
Phase 1 trial to investigate multiple B-cell mediated autoimmune diseases First healthy donor-derived allogeneic CAR T cell therapy to announce IND clearance Expect to disclose initial clinical data next year SEATTLE, Nov. 09, 2023 (G... Full story
Yahoo Finance • last year
Sana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual Meeting
SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that five abstracts will have poster presentations at t... Full story
Yahoo Finance • last year
Sana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with a 2024 Operating Burn under $200M
Increasing focus on ex vivo cell therapy platform based on extensive preclinical and early translational clinical data suggesting ability of hypoimmune (HIP)-modified cells to evade immune detection Human proof of concept data in multiple... Full story
Yahoo Finance • last year
Sana Biotechnology to Present at September 2023 Investor Conferences
SEATTLE, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at five investor... Full story
Yahoo Finance • last year
Sana Biotechnology Highlights Preclinical Data from Hypoimmune and Fusogen Platforms at the International Society for Stem Cell Research (ISSCR) 2023 Annual Meeting
Hypoimmune (HIP)-modified CD19-directed CAR T cells have the potential to serve as a universal off-the-shelf therapy that provides long-term durability of response without immunosuppression HIP-modified primary pancreatic islet cells alle... Full story
Yahoo Finance • 2 years ago
Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry
The company's MIMiC™ platform drives unprecedented insights into molecular interactions to design new biomolecules precisely tuned for therapeutic benefit With $50 million in committed capital from Flagship, Metaphore has built a first-in... Full story
Yahoo Finance • 2 years ago
Sana Biotechnology Highlights Preclinical Hypoimmune Data for its Allogeneic CAR T Platform and Advancements with its In Vivo Fusogen Platform with Four Presentations at the 2023 AACR Annual Meeting
Hypoimmune-modified CD19-directed CAR T cells persist and remain functional in preclinical models over multiple months in an allogeneic humanized immune system, even with tumor re-challenge SC291 IND cleared earlier in 2023, with initial... Full story
Yahoo Finance • 2 years ago
Sana Biotechnology Announces Preclinical Data Published in Nature Communications Demonstrating the Ability of its Hypoimmune Allogeneic CD19-directed CAR T Cells to Evade Immune Rejection and Produce Durable Anti-Tumor Responses
Hypoimmune-modified allogeneic CD19-directed CAR T cells can evade immune detection and kill tumor cells in a novel humanized allogeneic preclinical model in vivo, including following tumor cell reinjection Findings suggest that hypoimmun... Full story
Yahoo Finance • 2 years ago
Sana Biotechnology Announces Preclinical Data Published in Science Translational Medicine Showing its Hypoimmune Pancreatic Islet Cells Evaded Allogeneic and Autoimmune Rejection and Controlled Type 1 Diabetes in Preclinical Model
Hypoimmune human islet cells normalized glucose in diabetic humanized immunocompetent mouse model and avoided allogeneic and autoimmune rejection by the immune system Similar hypoimmune primary human islet cells to be tested in patients w... Full story
Yahoo Finance • 2 years ago
Sana Biotechnology Announces the Appointment of Two Pioneers in Drug Discovery and Development to Lead its R&D Organization
Dr. Douglas E. Williams as Head of Research and Development Dr. Gary Meininger as Chief Medical Officer SEATTLE, April 10, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for... Full story
Yahoo Finance • 2 years ago
Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
Announced SC291 IND clearance with goal to report initial clinical data this year Expect to initiate investigator-sponsored trial with hypoimmune-modified primary islet cells with potential clinical data this year Goal to submit two INDs... Full story
Yahoo Finance • 2 years ago
Sana Biotechnology Announces the Acceptance of Four Abstracts for Presentation at the 2023 American Association for Cancer Research Annual Meeting
SEATTLE, March 14, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that four abstracts, including a late-breaking abstract, hig... Full story
Yahoo Finance • 2 years ago
Sana Biotechnology to Present at the Cowen 43rd Annual Health Care Conference
SEATTLE, March 01, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Cowen 43rd Annu... Full story
Yahoo Finance • 2 years ago
Charles River and Flagship’s Pioneering Medicines Enter Agreement Leveraging AI-Powered Logica with Aim of Creating Novel Therapies for Unmet Medical Needs
Logica, an offering from Charles River and Valo Health will be deployed by Pioneering Medicines across a portfolio of targets WILMINGTON, Mass. & CAMBRIDGE, Mass., February 16, 2023--(BUSINESS WIRE)--Charles River Laboratories Internation... Full story
Yahoo Finance • 2 years ago
Sana Biotechnology to Present at the Guggenheim Healthcare Talks 5th Annual Oncology Conference
SEATTLE, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Guggenheim Healt... Full story
